X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9899) 9899
Publication (1127) 1127
Book Review (93) 93
Book Chapter (64) 64
Newsletter (29) 29
Book / eBook (12) 12
Conference Proceeding (12) 12
Dissertation (4) 4
Magazine Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6281) 6281
animals (3366) 3366
index medicus (3326) 3326
pharmacology & pharmacy (2347) 2347
topoisomerase ii inhibitors (2342) 2342
antineoplastic agents - pharmacology (2251) 2251
oncology (2117) 2117
biochemistry & molecular biology (1897) 1897
topoisomerase i inhibitors (1790) 1790
enzyme inhibitors - pharmacology (1748) 1748
chemistry, medicinal (1725) 1725
cell line, tumor (1580) 1580
cancer (1489) 1489
mice (1470) 1470
camptothecin - pharmacology (1464) 1464
apoptosis (1375) 1375
dna topoisomerases, type ii - metabolism (1329) 1329
dna topoisomerases, type i - metabolism (1176) 1176
female (1175) 1175
structure-activity relationship (1174) 1174
dna (1171) 1171
dna damage (1171) 1171
camptothecin (1152) 1152
apoptosis - drug effects (1059) 1059
tumor cells, cultured (1024) 1024
dose-response relationship, drug (975) 975
camptothecin - analogs & derivatives (959) 959
etoposide - pharmacology (909) 909
antineoplastic agents - chemistry (885) 885
male (874) 874
topoisomerase-ii (865) 865
cytotoxicity (820) 820
dna - metabolism (798) 798
molecular structure (777) 777
antineoplastic agents, phytogenic - pharmacology (771) 771
cell biology (765) 765
chemotherapy (762) 762
topoisomerase-i (753) 753
drug screening assays, antitumor (746) 746
cell survival - drug effects (725) 725
cell proliferation - drug effects (713) 713
inhibitors (679) 679
antineoplastic agents - chemical synthesis (676) 676
analysis (668) 668
anti-bacterial agents - pharmacology (668) 668
derivatives (658) 658
cell line (652) 652
mechanism (649) 649
etoposide (646) 646
drug resistance (620) 620
research (607) 607
topoisomerase ii inhibitors - pharmacology (607) 607
mutation (597) 597
expression (596) 596
cells (593) 593
inhibition (593) 593
microbiology (592) 592
dna topoisomerase (582) 582
neoplasms - drug therapy (576) 576
drugs (564) 564
cell cycle - drug effects (545) 545
chemistry, organic (545) 545
microbial sensitivity tests (527) 527
article (519) 519
models, molecular (509) 509
topoisomerase i inhibitors - pharmacology (506) 506
binding (498) 498
resistance (498) 498
topotecan (477) 477
in-vitro (474) 474
proteins (468) 468
cell cycle (467) 467
research article (464) 464
enzymes (461) 461
topoisomerase (457) 457
phosphorylation (447) 447
topoisomerase ii (447) 447
dna topoisomerases, type ii - genetics (442) 442
antineoplastic agents - therapeutic use (439) 439
deoxyribonucleic acid--dna (431) 431
escherichia-coli (431) 431
drug resistance, neoplasm (427) 427
drug design (424) 424
dna gyrase (420) 420
dna topoisomerase-ii (419) 419
dna-binding proteins - metabolism (416) 416
rats (415) 415
dna topoisomerase-i (412) 412
dna repair (410) 410
antitumor-activity (407) 407
doxorubicin - pharmacology (405) 405
irinotecan (405) 405
agents (400) 400
kinetics (400) 400
toxicology (397) 397
enzyme inhibitors - chemistry (393) 393
molecular sequence data (392) 392
cell division - drug effects (382) 382
dna topoisomerases (381) 381
topoisomerase i (377) 377
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9821) 9821
Japanese (31) 31
Russian (31) 31
French (27) 27
German (21) 21
Chinese (11) 11
Spanish (11) 11
Italian (5) 5
Portuguese (4) 4
Polish (2) 2
Slovenian (2) 2
Turkish (2) 2
Czech (1) 1
Finnish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 5097 - 5108
Purpose: An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its... 
ANTIBODY-DRUG CONJUGATE | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | NEU ONCOGENE | METASTATIC BREAST-CANCER | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | PANCREATIC ADENOCARCINOMA | MULTIDRUG-RESISTANCE | TRASTUZUMAB EMTANSINE | AMERICAN SOCIETY | Humans | Immunoconjugates - pharmacokinetics | Macaca fascicularis | Maytansine - pharmacology | Pancreatic Neoplasms - drug therapy | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Trastuzumab - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Maytansine - analogs & derivatives | Rats | Breast Neoplasms - drug therapy | Checkpoint Kinase 1 - metabolism | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Histones - metabolism | Antibody-Dependent Cell Cytotoxicity - drug effects | Camptothecin - pharmacology
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 403, pp. 98 - 107
Abstract Organometallic complexes offer the prospect of targeting multiple pathways that are important in cancer biology. Here, the preclinical activity and... 
Hematology, Oncology and Palliative Medicine | Thioredoxin reductase inhibitor | Silver-N-heterocyclic carbene | PARP1 inhibitor | Topoisomerase inhibitor | Glycolytic inhibitor | TARGET | APOPTOSIS | DNA-BINDING | MAMMALIAN THIOREDOXIN | CANCER | ONCOLOGY | THIOREDOXIN REDUCTASE | AGENTS | INHIBITORS | TUMOR-GROWTH | CYTOTOXICITY | Neoplasms - metabolism | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Imidazoles - chemistry | Drug Resistance, Neoplasm | Glycolysis - drug effects | Antineoplastic Agents - toxicity | Antineoplastic Combined Chemotherapy Protocols - pharmacology | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Topoisomerase I Inhibitors - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antigens, Neoplasm - metabolism | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Imidazoles - toxicity | Cell Survival - drug effects | DNA Topoisomerases, Type II - metabolism | Organometallic Compounds - toxicity | DNA Topoisomerases, Type I - metabolism | Poly (ADP-Ribose) Polymerase-1 - metabolism | Imidazoles - pharmacology | Topoisomerase II Inhibitors - pharmacology | Cisplatin - pharmacology | Antineoplastic Agents - chemistry | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Neoplasms - drug therapy | Drug Synergism | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Signal Transduction - drug effects | Cell Line, Tumor | Thioredoxin Reductase 1 - antagonists & inhibitors | Organometallic Compounds - chemistry | DNA Damage | Oxidative Stress - drug effects | Neoplasms - pathology | Organometallic Compounds - pharmacology | Thioredoxin Reductase 1 - metabolism | Glucose metabolism | Enzymes | Care and treatment | Cell death | Heterocyclic compounds | DNA damage | Cancer | Flow cytometry | Reactive oxygen species | Toxicity | Cytotoxicity | Biology | Thioredoxin | Kinases | Cancer therapies | DNA repair | Anticancer properties | Fibers | Pathways | Inhibition | Coordination compounds | Deoxyribonucleic acid--DNA | Gold | Damage assessment | DNA topoisomerase | Organometallic complexes | Cisplatin | Silver | Poly(ADP-ribose) Polymerase 1 | Glycolysis | Ligands | Temozolomide | Tumors | Apoptosis | Reductase
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2017, Volume 141, Issue 8, pp. 1682 - 1689
Anti‐HER2 therapies are beneficial for patients with HER2‐positive breast or gastric cancer. T‐DM1 is a HER2‐targeting antibody–drug conjugate (ADC) comprising... 
ADC | gastric cancer | HER2 | ABC transporter | T‐DM1 | T-DM1 | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | TUMORS | TRASTUZUMAB EMTANSINE | BREAST-CANCER | POTENT | AMPLIFICATION | ONCOLOGY | DX-8951F | PLUS | Camptothecin - chemistry | Humans | Drug Resistance, Neoplasm | Maytansine - pharmacology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Topoisomerase I Inhibitors - chemistry | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Receptor, ErbB-2 - biosynthesis | Maytansine - analogs & derivatives | Random Allocation | Stomach Neoplasms - drug therapy | Immunoconjugates - chemistry | Stomach Neoplasms - immunology | Animals | Mice, Nude | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Camptothecin - pharmacology | Trastuzumab | Antibodies, Monoclonal, Humanized - chemistry | Viral antibodies | Analysis | DNA | DNA topoisomerase I | Antibodies | Genetic aspects | Stomach cancer | Biopharmaceutics | Cancer | Efflux | DNA topoisomerase | Breast cancer | Drug resistance | Patients | ErbB-2 protein | Epidermal growth factor | Inhibitors | Tubulin | Xenografts | Breast | ATP-binding protein | Inhibition | Aberration | Gastric cancer | ATP | In vitro methods and tests | Deoxyribonucleic acid--DNA
Journal Article
Journal Article
Science, ISSN 0036-8075, 05/2016, Volume 352, Issue 6289, pp. aad7993 - aad7993
The host innate immune response is the first line of defense against pathogens and is orchestrated by the concerted expression of genes induced by microbial... 
RNA-POLYMERASE-II | BROMODOMAINS | VIRUS | CAMPTOTHECIN | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION | DISEASE | INFLUENZA | RIG-I | CPG ISLANDS | EXPRESSION | Transcription, Genetic - drug effects | Interferon-beta - immunology | Sendai virus | Humans | Positive Transcriptional Elongation Factor B - antagonists & inhibitors | Host-Pathogen Interactions - drug effects | RNA Polymerase II - metabolism | Flavonoids - therapeutic use | Topoisomerase I Inhibitors - pharmacology | Piperidines - pharmacology | Inflammation - drug therapy | HEK293 Cells | Flavonoids - pharmacology | Hemorrhagic Fever, Ebola - drug therapy | Staphylococcus aureus | Triazoles - therapeutic use | Ebolavirus | Inflammation - microbiology | Staphylococcal Infections - drug therapy | Camptothecin - therapeutic use | DNA Topoisomerases, Type I - metabolism | Mice, Inbred C57BL | Immunity, Innate | Topotecan - therapeutic use | Azepines - therapeutic use | Azepines - pharmacology | Gene Expression Regulation - drug effects | Triazoles - pharmacology | Animals | Host-Pathogen Interactions - genetics | Influenza A virus | Piperidines - therapeutic use | Topoisomerase I Inhibitors - therapeutic use | Inflammation - genetics | Mice | Camptothecin - pharmacology | Pathogens | Inflammation | Gene expression | Immune system | Winding | Genes | Deoxyribonucleic acid | Bacteria | Viruses | Pharmacology | Inhibition
Journal Article
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 01/2018, Volume 143, pp. 1563 - 1577
Journal Article
Journal Article